Histrelin (Supprelin LA/Vantas) - Complete Research Paper

1. Summary

Histrelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist delivered via a long-acting subcutaneous implant providing continuous drug release for 12 months. This unique delivery system distinguishes histrelin from other GnRH agonists that require monthly or quarterly injections. Two brand formulations have been marketed: Vantas (prostate cancer) and Supprelin LA (central precocious puberty), though Vantas has been discontinued since 2020, leaving Supprelin LA as the only available histrelin product.

Supprelin LA was FDA-approved in May 2007 for the treatment of central precocious puberty (CPP) in children, while Vantas received FDA approval in October 2004 for palliative treatment of advanced prostate cancer. Both formulations contain 50 mg histrelin acetate in a small, flexible subcutaneous implant inserted in the inner upper arm.

The mechanism of action parallels other GnRH agonists: initial stimulation of pituitary gonadotropins followed by receptor downregulation and sustained suppression of the hypothalamic-pituitary-gonadal axis. This results in prepubertal hormone levels in CPP children and castrate testosterone levels in prostate cancer patients.

Key advantages of the histrelin implant include once-yearly dosing (reducing injection burden) and continuous, consistent drug delivery eliminating peak-trough fluctuations. Research has demonstrated efficacy for up to 2 years with a single implant in CPP, potentially reducing the number of procedures required. However, the implant requires surgical insertion and removal, and significant cost differences exist between formulations (Supprelin LA ~$45,000 vs. formerly Vantas ~$5,400).

Common adverse effects include implant site reactions (bruising, pain, redness), initial flare of pubertal symptoms in CPP, and behavioral changes in pediatric patients (irritability, mood changes). Serious but rare adverse events include systemic allergic reactions and difficulty with implant removal if migration occurs.

2. Mechanism of Action

Histrelin acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). The molecule features amino acid substitutions that enhance receptor binding affinity and confer resistance to enzymatic degradation, providing extended biological activity compared to endogenous GnRH.

Initial Agonist Phase: Upon implant insertion and drug release initiation, histrelin binds to and activates GnRH receptors on anterior pituitary gonadotroph cells. This produces an initial stimulatory response:

Pituitary Response:

• Increased release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
• Transient elevation lasting 1-2 weeks

Gonadal Effects:

• Males: Testosterone surge (may temporarily worsen prostate cancer symptoms)
• Females: Transient estradiol elevation
• Children with CPP: Brief worsening of pubertal signs possible

Sustained Suppression Phase: Continuous GnRH receptor stimulation leads to progressive desensitization and downregulation:

Receptor Changes:

• GnRH receptor internalization and decreased surface expression
• Reduced gonadotroph responsiveness to GnRH stimulation
• Effective "pituitary desensitization"

Hormonal Consequences (by weeks 2-4):

• Profound suppression of LH and FSH secretion
• Males: Testosterone reduction to castrate levels (<50 ng/dL)
• Females/Children: Estradiol suppression to prepubertal/postmenopausal levels
• Cessation of pubertal progression in CPP

Therapeutic Applications:

Central Precocious Puberty:

• Arrests premature hypothalamic-pituitary-gonadal activation
• Halts progression of secondary sexual characteristics
• Prevents premature epiphyseal fusion (preserving height potential)
• LH levels decrease to prepubertal range
• Effects are fully reversible upon implant removal

Prostate Cancer (Vantas - discontinued):

• Achieved medical castration equivalent to surgical orchiectomy
• Testosterone suppression slowed tumor growth
• Provided palliative benefit in advanced disease

Pharmacodynamic Profile:

• Implant delivers continuous 50-65 mcg histrelin daily
• Steady-state suppression maintained throughout 12-month implant life
• No peak-trough variations seen with injection formulations
• Suppression may extend beyond 12 months (research shows efficacy to 24+ months)

3. FDA-Approved Indications

Supprelin LA (FDA Approved May 2007):

• Treatment of children with central precocious puberty (CPP)
• Age criteria: Girls usually 2-8 years; Boys usually 2-9 years
• Diagnosis must confirm central (gonadotropin-dependent) origin
• Implant replaced every 12 months until appropriate age for puberty
• Treatment discontinued at approximately age 11 in girls, 12 in boys

Vantas (FDA Approved October 2004 - DISCONTINUED):

• Palliative treatment of advanced prostate cancer
• Provided 12-month testosterone suppression
• Discontinued by Endo Pharmaceuticals September 2021
• Manufacturing issues cited (batches not meeting specifications)
• No longer available; Supprelin LA is NOT approved for prostate cancer

Off-Label Uses:

• Gender-affirming puberty suppression in transgender youth
• Endometriosis (investigational)
• Uterine fibroids (investigational)
• Advanced prostate cancer (using Supprelin LA off-label post-Vantas discontinuation)

Important Distinctions:

• Supprelin LA and Vantas, while both containing 50 mg histrelin acetate, were NOT identical products per manufacturer
• Drug release rates differ slightly (65 mcg/day vs. 50 mcg/day)
• Supprelin LA is specifically formulated for pediatric CPP
• Off-label use for prostate cancer must consider these differences

4. Dosing and Administration

Formulation:

• Supprelin LA: 50 mg histrelin acetate in flexible subcutaneous implant
• Dimensions: Approximately 3 cm long × 3 mm diameter (small, cylindrical)
• Drug release: 65 mcg histrelin acetate per day (equivalent to 52 mcg histrelin base)
• Duration: Designed for 12 months of continuous release

Dosing:

• One implant every 12 months
• Implant provides continuous release; no need for supplemental injections
• Built-in flexibility for appointment scheduling (slight overdesign allows extra weeks)
• Replace at 12 months or when appropriate based on clinical assessment

Insertion Procedure:

1. Performed by physician (typically pediatric surgeon or endocrinologist)
2. Location: Inner aspect of upper arm, subcutaneously
3. Anesthesia: Local anesthesia for older children; sedation or general anesthesia may be needed for young or anxious children
4. Technique:
   • Sterile gloves and aseptic technique required
   • Small incision made in skin
   • Implant inserted subdermally using trocar
   • Incision closed with sutures or adhesive strips
   • Pressure bandage applied
5. Post-procedure: Monitor for bleeding, infection; wound care instructions

Removal Procedure:

1. Required at end of treatment or for implant replacement
2. Palpate implant location before procedure
3. If implant difficult to locate (migration), use ultrasound or MRI
4. Local anesthesia; make small incision over implant
5. Extract implant carefully
6. If replacing, new implant may be inserted through same incision site
7. Wound closure and post-procedure monitoring

Discontinuation Timing:

• At physician discretion based on appropriate timing for natural puberty
• Girls: Approximately 11 years of age
• Boys: Approximately 12 years of age
• Remove implant even if medication depleted (device must be extracted)

Unique Considerations:

• Not self-administered; requires surgical procedure
• Minimally invasive but requires appropriate surgical setting
• Children requiring multiple years of therapy need annual procedures
• Extended use (>12 months) may be considered based on research showing 24-month efficacy

5. Pharmacokinetics

Absorption:

• Route: Continuous subcutaneous release from implanted device
• Release rate: 65 mcg/day (Supprelin LA) or 50 mcg/day (Vantas)
• Bioavailability: ~90% from subcutaneous depot
• Time to steady-state: Within first week of implantation
• Peak serum concentration: ~1.2 ng/mL (mean)

Distribution:

• Volume of distribution: Approximately 58 L
• Protein binding: 70% (predominantly to albumin)
• Tissue distribution: Primarily pituitary gland (target organ)
• Does not significantly cross blood-brain barrier

Metabolism:

• Pathway: Hepatic and renal peptidase degradation
• No involvement of cytochrome P450 enzymes
• Metabolites: Inactive peptide fragments
• No active metabolites identified

Elimination:

• Half-life: 4 hours (terminal, after implant removal)
• Clearance: Not precisely characterized
• Excretion: Primarily renal (metabolites)
• Complete elimination after implant removal: 24-48 hours

Duration of Effect:

• Single implant: Designed for 12 months of continuous suppression
• Extended efficacy demonstrated up to 24+ months in research
• Suppression "escape" reported at 15-65 months in extended use studies
• Recovery after removal: Hormonal function returns within 2-6 months

Pediatric Pharmacokinetics:

• Similar to adults on weight-adjusted basis
• Steady-state achieved within days of implantation
• Consistent drug delivery across age range (2+ years)
• Body weight does not require dose adjustment

Special Populations:

• Renal impairment: No formal studies; caution advised
• Hepatic impairment: No formal studies; likely safe given non-hepatic metabolism
• No dose adjustment for age, weight, or organ function
• Standardized implant used across all patients

6. Side Effects and Adverse Reactions

Very Common (>10% incidence):

Implant Site Reactions:

• Bruising at insertion/removal site: 30-50%
• Pain/discomfort at implant site: 20-40%
• Redness/erythema: 15-25%
• Swelling/induration: 10-20%
• Itching at site: 5-15%

Initial Flare Effects (First 2-4 Weeks):

• Worsening of pubertal signs in CPP: 10-20%
• Light vaginal bleeding in girls: 5-15%
• Breast enlargement in girls: 5-10%
• Increased testicular size/erections in boys: 5-10%
• Hot flashes: Variable (more common in prostate cancer)

Common (1-10% incidence):

Behavioral/Psychiatric (Pediatric):

• Irritability: 5-10%
• Mood swings/emotional lability: 5-10%
• Agitation/restlessness: 3-6%
• Sleep disturbances: 3-5%
• Increased energy/hyperactivity: 2-5%

Systemic Effects:

• Headache: 5-10%
• Weight gain: 3-8%
• Fatigue: 2-5%
• Nausea: 2-4%

Dermatological:

• Acne: 3-5%
• Rash (non-injection site): 2-3%

Serious Adverse Reactions:

Allergic Reactions:

• Severe systemic allergic reactions: Rare (<1%)
• Anaphylaxis requiring emergent implant removal: Reported (2 cases in literature)
• Angioedema: Rare
• Symptoms may include urticaria, dyspnea, hypotension
• May require immediate implant removal

Implant Complications:

• Implant migration: Infrequent but makes removal difficult
• Implant breakage during removal: Rare
• Infection at insertion site: <2%
• Bleeding/hematoma requiring intervention: <1%
• Scarring at insertion/removal sites: Variable

Psychiatric Concerns (Pediatric):

• New or worsening behavioral problems
• Aggression or violent feelings
• Anxiety, fearfulness
• Depression symptoms
• Requires monitoring and potential intervention

Bone Density Concerns (Long-term):

• Potential impact on bone mineral accrual in pediatric patients
• Long-term data limited
• Most studies show recovery after treatment discontinuation

Prostate Cancer-Specific (Vantas - Historical):

Tumor Flare:

• Transient worsening of symptoms during first 2 weeks
• Bone pain exacerbation
• Spinal cord compression risk with vertebral metastases
• Urinary obstruction possible

Cardiovascular:

• FDA warning (class effect): Increased diabetes, MI, stroke risk
• Similar to other GnRH agonists

7. Drug Interactions

Clinically Significant Interactions:

QT-Prolonging Medications:

• GnRH agonists may contribute to QT prolongation (androgen deprivation effect)
• Use caution with:
  • Antiarrhythmics (amiodarone, sotalol, quinidine)
  • Antipsychotics (haloperidol, ziprasidone)
  • Fluoroquinolones
  • Macrolide antibiotics
• Consider baseline ECG monitoring if combining

Hypoglycemic Agents:

• Androgen deprivation associated with insulin resistance
• Primarily relevant to prostate cancer (Vantas - discontinued)
• Monitor glucose in diabetic patients

Moderate Interactions:

Anticoagulants:

• Theoretical interaction (case reports with other GnRH agonists)
• Monitor for bleeding at surgical insertion/removal sites
• INR monitoring in warfarin patients undergoing procedures

Corticosteroids:

• May compound bone density effects
• Consider bone protection if long-term concurrent use

Drugs with No Significant Interactions:

No CYP450 Interactions:

• Histrelin metabolized by peptidases, not hepatic CYP enzymes
• No dose adjustments needed for most concurrent medications
• Safe with common pediatric medications:
  • Antibiotics
  • Antihistamines
  • NSAIDs
  • Asthma medications

Vaccines:

• No contraindication to routine childhood immunizations
• Standard vaccine schedule may be followed

Procedural Considerations:

Anesthesia Interactions:

• No specific contraindications to anesthetics
• Standard anesthesia protocols apply for insertion/removal
• Monitor for allergic reactions peri-procedurally

Contrast Agents:

• If MRI needed to locate implant, standard protocols apply
• Implant is MRI-compatible

Laboratory Test Interference:

• Suppresses LH, FSH, testosterone/estradiol (therapeutic effect)
• No interference with routine laboratory panels
• Bone age X-rays should reflect slowed maturation

8. Contraindications

Absolute Contraindications:

Hypersensitivity:

• Known hypersensitivity to histrelin, GnRH, GnRH agonists
• Previous anaphylaxis to GnRH analog
• Allergy to any component of the implant device

Pregnancy (Category X):

• Contraindicated in pregnancy
• May cause fetal harm
• Not applicable to primary CPP indication (prepubertal children)
• Relevant if used off-label in reproductive-age women

Breastfeeding:

• Not recommended during lactation
• Unknown if excreted in breast milk
• Not applicable to CPP population

Relative Contraindications/Precautions:

Patients Unable to Undergo Surgical Procedure:

• Bleeding disorders (relative)
• Severe thrombocytopenia
• Active infection at planned insertion site
• Keloid formation history (cosmetic concern)

Psychiatric Conditions (Pediatric):

• Pre-existing behavioral disorders may be exacerbated
• Monitor closely if history of:
  • ADHD
  • Aggression/conduct disorder
  • Anxiety disorders
  • Depression

Age Limitations:

• Safety not established in children under 2 years
• Appropriate diagnosis of CPP essential before initiation

Bone Health Concerns:

• Pre-existing osteopenia/osteoporosis
• Conditions affecting bone metabolism
• Consider bone health monitoring

Allergy History:

• Patients with history of medication allergies
• Monitor closely after insertion
• Have emergency protocols available

Prostate Cancer Precautions (Historical - Vantas):

• Vertebral metastases (spinal cord compression risk)
• Urinary obstruction (acute retention risk)
• Cardiovascular disease
• These were relevant when Vantas was available

9. Special Populations

Pediatric Patients:

• Primary indicated population for Supprelin LA
• Approved for children ≥2 years with CPP
• Girls: Typically 2-8 years at diagnosis
• Boys: Typically 2-9 years at diagnosis
• Younger children may require sedation/general anesthesia for procedure
• Behavioral side effects more prominent than in adults
• Monitor for mood changes, irritability, aggression
• Annual implant replacement until appropriate age for natural puberty
• Growth and development should be monitored closely
• Bone age assessment recommended periodically

Adolescent/Transgender Patients:

• Off-label use for puberty suppression in gender dysphoria
• Extended implant duration studied (up to 65 months in some cases)
• Provides reversible pubertal suppression
• Continued until decision regarding gender-affirming hormones
• Supprelin LA preferred over discontinued Vantas

Adult Patients (Prostate Cancer - Historical):

• Vantas was approved for advanced prostate cancer
• Since discontinuation, limited histrelin options for adults
• Off-label use of Supprelin LA theoretically possible but:
  • Not FDA-approved for prostate cancer
  • Significantly higher cost
  • Formulation differences from Vantas

Geriatric Patients:

• Most prostate cancer patients are elderly
• Vantas discontinuation limits geriatric use of histrelin
• Other GnRH agonists (leuprolide, goserelin) available

Renal Impairment:

• No formal pharmacokinetic studies
• Peptide metabolites eliminated renally
• Standard dosing typically used; monitor for accumulation

Hepatic Impairment:

• No formal pharmacokinetic studies
• Non-hepatic metabolism (peptidases)
• Standard dosing typically appropriate

Pregnancy:

• Category X: Contraindicated
• Not applicable to typical CPP population
• Relevant for off-label use in reproductive-age females

Lactation:

• Unknown if excreted in breast milk
• Not recommended during breastfeeding
• Not applicable to pediatric CPP population

Obese Patients:

• Standard implant used regardless of weight
• Insertion technique may require adjustment
• Ensure subcutaneous placement (not too deep)
• Drug release not affected by body weight

10. Monitoring Parameters

Baseline Assessment (Before Implant Insertion):

Diagnostic Confirmation of CPP:

• GnRH stimulation test confirming central origin
• Bone age assessment (X-ray)
• LH, FSH, testosterone (boys), estradiol (girls)
• Brain MRI (rule out CNS pathology)
• Tanner staging assessment
• Height and weight measurements

Pre-Procedure Assessment:

• Complete blood count (CBC)
• Coagulation studies if bleeding history
• Review of medication allergies
• Anesthesia clearance if sedation planned
• Arm examination for insertion site selection

Immediate Post-Insertion Monitoring:

• Wound healing assessment
• Monitor for bleeding, hematoma
• Watch for signs of infection (redness, warmth, purulent drainage)
• Allergic reaction surveillance (particularly first 24-48 hours)
• Palpate implant to confirm position

Ongoing Monitoring - Central Precocious Puberty:

Hormonal Assessment (Every 3-6 Months):

• LH (should be suppressed to prepubertal levels)
• FSH (suppressed)
• Testosterone (boys) or estradiol (girls) - suppressed
• If breakthrough suspected, may perform GnRH stimulation test

Growth and Development:

• Height and weight: Every 3-6 months
• Growth velocity calculation
• Bone age: Every 6-12 months
• Tanner staging: Every visit

Behavioral Monitoring:

• Mood and behavior assessment each visit
• Screen for irritability, aggression, depression
• Sleep pattern changes
• School performance

Implant Assessment:

• Palpate implant at each visit to confirm position
• Note if implant feels intact
• If not palpable, imaging may be needed before removal

At Time of Implant Replacement (12 Months):

• Full hormonal assessment
• Growth evaluation
• Decision: Replace, extend, or discontinue based on age and response
• Surgical site examination

Discontinuation/End of Treatment:

• Remove implant surgically
• Monitor for return of pubertal progression
• Expected: Pubertal signs should resume within months
• Follow growth and development through natural puberty

11. Cost and Availability

Brand Name Products:

Supprelin LA (Currently Available):

• Cost: ~$43,000-47,000 per implant (WAC/AWP)
• Manufacturer: Endo Pharmaceuticals
• Annual cost with yearly replacement: ~$45,000+
• Specialty pharmacy distribution
• One of the most expensive GnRH agonist options

Vantas (DISCONTINUED - September 2021):

• Historical cost: ~$5,000-5,400 per implant
• Was significantly less expensive than Supprelin LA
• Manufacturing issues led to discontinuation
• No longer available in any market

Cost Comparison:

| Product | Annual Cost | Dosing | |------

Goal Relevance:

• Manage early puberty in children to prevent premature growth and development.
• Support hormone regulation in children experiencing central precocious puberty.
• Provide a long-term solution for hormone suppression in children, reducing the frequency of medical procedures.
• Alleviate symptoms associated with hormone-related conditions in children, such as mood swings and irritability.
• Preserve height potential in children by halting early bone growth associated with precocious puberty.
• Offer a reversible treatment option for managing early puberty, allowing normal development to resume when appropriate.
• Explore potential off-label use for managing hormone levels in transgender youth undergoing puberty suppression.

---|-------------|--------| | Supprelin LA | ~$45,000 | 1 implant/year | | Lupron Depot-Ped | ~$15,000-20,000 | Monthly/3-month IM | | Triptodur | ~$25,000 | Every 6 months IM | | Vantas (historical) | ~$5,400 | 1 implant/year |

Insurance Coverage:

• Prior authorization universally required
• Often requires documentation of CPP diagnosis
• May require trial of less expensive alternatives first
• Specialty pharmacy coordination needed
• Appeals may be necessary for coverage approval
• Pediatric endocrinologist documentation typically required

Patient Assistance Programs:

• Endo Pharmaceuticals patient assistance available
• Income-based eligibility
• Copay assistance programs
• Foundation support for pediatric medications
• Social worker involvement often helpful

Economic Considerations:

• Annual surgical costs for insertion/removal add to total expense
• Anesthesia costs if sedation required
• Office visit costs for monitoring
• Extended implant use (2+ years) could reduce procedure costs
• No generic histrelin implants available

Availability:

• Supprelin LA: Available in US through specialty distributors
• Requires refrigerated storage and cold chain
• Healthcare facility must have surgical capability for insertion
• Typically administered at pediatric specialty centers
• Some adult off-label use may face access barriers

12. Clinical Evidence Summary

Central Precocious Puberty - Pivotal Trials:

Phase 3 Registration Study:

• Open-label study in children with CPP
• Demonstrated sustained LH suppression throughout 12-month treatment
• LH response to GnRH stimulation suppressed to prepubertal levels
• Pubertal progression halted
• Growth velocity normalized
• Bone age advancement slowed

Long-Term Extension Studies:

• Continued efficacy demonstrated over multiple years
• Annual implant replacement maintained suppression
• Height outcomes comparable to other GnRH agonists
• Puberty resumed appropriately after treatment discontinuation

Extended Use Studies (Beyond 12 Months):

2-Year Single Implant Study (2014):

• Demonstrated continued HPG axis suppression with single implant for 24 months
• Excellent clinical response maintained
• Reduced cost and number of procedures
• Sustained biochemical and clinical pubertal suppression

Extended Use Analysis (2023):

• Studied implant duration ranging from 15-65 months
• Most patients maintained suppression throughout extended use
• Suppression "escape" occurred in some patients at various timepoints
• Complications at removal were infrequent
• Supports extended use strategy to reduce procedures and cost

Comparative Studies:

Histrelin vs. Leuprolide/Triptorelin:

• Comparable efficacy in achieving pubertal suppression
• Implant offers convenience advantage (once-yearly vs. monthly/quarterly)
• Higher initial cost offset by fewer procedures
• Similar safety profiles

50 mcg/day vs. 65 mcg/day Comparison (Gender Dysphoria):

• Both Vantas (50 mcg/day) and Supprelin LA (65 mcg/day) effective
• Both achieved adequate pubertal suppression
• Supprelin LA (65 mcg/day) preferred for pediatric use
• Vantas was previously used off-label at lower cost

Safety Data:

Allergic Reactions:

• Two published cases of severe systemic allergic reactions
• Required emergent implant removal
• Rare but important safety signal

Surgical Complications:

• Difficulty in 39% of patients in one surgical outcomes study
• Experienced surgeon important for optimal outcomes
• Implant migration can complicate removal
• Overall complication rate acceptable

13. Comparison with Alternatives

GnRH Agonists for CPP:

Key Differentiators for Histrelin:

Advantages:

1. Once-yearly dosing: Significant convenience for families
2. Continuous drug release: No peak-trough fluctuations
3. Extended use potential: May last 2+ years in some patients
4. Reduced injection anxiety: No repeated needle sticks

Disadvantages:

1. Surgical requirement: Insertion and removal require minor surgery
2. Highest cost: Most expensive CPP treatment option
3. Anesthesia needs: Young children often require sedation
4. Single product: Vantas discontinuation limits options
5. Removal challenges: Implant migration can complicate extraction

Clinical Decision Factors:

Choose Histrelin When:

• Family strongly prefers reduced treatment frequency
• Child has severe needle phobia
• Expected treatment duration is multiple years
• Resources available for surgical procedures
• Insurance provides coverage

Choose Leuprolide/Triptorelin When:

• Cost is significant concern
• Surgical procedure not desired or feasible
• Shorter treatment course anticipated
• Insurance favors injection formulations
• Child tolerates injections well

Prostate Cancer Alternatives (Post-Vantas):

Since Vantas discontinuation, prostate cancer patients must use:

• Leuprolide (Lupron Depot, Eligard)
• Goserelin (Zoladex)
• Triptorelin (Trelstar)
• Degarelix (GnRH antagonist)
• Relugolix (oral GnRH antagonist)

14. Storage and Handling

Storage Requirements:

Supprelin LA:

• Store refrigerated at 2-8°C (36-46°F)
• Keep in original carton to protect from light
• Do not freeze
• Bring to room temperature before insertion (optional)
• Check expiration date before use
• Single-use; do not re-sterilize

Pre-Procedure Handling:

1. Remove from refrigerator before procedure
2. Allow to reach room temperature if desired (reduces insertion discomfort)
3. Inspect packaging for damage or tampering
4. Verify expiration date
5. Open package using sterile technique
6. Use immediately after opening

Insertion Kit Contents:

• Histrelin implant (flexible tube containing drug)
• Insertion device/trocar
• Instructions for use
• Sterile gloves and drapes in separate kit

Surgical Setting Requirements:

• Sterile field
• Local anesthesia capability
• Sedation/anesthesia availability for pediatric patients
• Appropriate lighting
• Emergency equipment available (allergic reaction risk)

Implant Handling:

• Handle with sterile gloves
• Avoid bending or damaging implant
• Insert per manufacturer instructions
• Do not attempt to reload or reuse insertion device

Post-Procedure:

• Apply pressure dressing
• Provide wound care instructions
• Patient should avoid heavy use of arm for 24-48 hours
• Keep site clean and dry
• Remove dressing per physician instructions

Disposal:

• Dispose of used insertion device in sharps container
• Removed implants: Dispose as pharmaceutical waste
• Follow local regulations for medical waste
• No special hazardous material handling required

Cold Chain Considerations:

• Transport in insulated container with cold packs
• Avoid temperature excursions
• Verify temperature upon receipt at facility
• Do not use if frozen or temperature-compromised

15. Goal Archetype Integration

Histrelin's unique delivery mechanism and sustained hormonal suppression profile align with specific therapeutic archetypes where long-term hypothalamic-pituitary-gonadal axis modulation is required.

GnRH Agonist Implant Archetype

Core Mechanism: Histrelin represents the implant-based GnRH agonist archetype, distinguished by:

• Continuous, non-pulsatile drug release eliminating injection burden
• Surgical insertion/removal requirement
• Extended duration (12-24+ months per implant)
• Complete hypothalamic-pituitary desensitization

Archetype Positioning:

Central Precocious Puberty Archetype

Patient Profile:

• Age: Girls 2-8 years, Boys 2-9 years at diagnosis
• Presentation: Premature secondary sexual characteristics
• Diagnostic confirmation: GnRH stimulation test positive
• Goal: Halt pubertal progression, preserve adult height potential

Therapeutic Objectives:

1. Primary: Suppress gonadotropin-driven puberty
2. Growth Preservation: Prevent premature epiphyseal fusion
3. Psychosocial: Normalize development timeline with peers
4. Reversibility: Allow natural puberty at appropriate age

Histrelin Fit:

• Ideal for multi-year treatment courses (reduces procedure count)
• Consistent suppression without peak-trough fluctuations
• Well-suited for needle-phobic children
• Continuous release matches slow disease progression

Treatment Duration Framework:

Prostate Cancer Archetype (Historical - Vantas)

Patient Profile:

• Age: Typically 65+ years
• Diagnosis: Advanced/metastatic prostate cancer
• Goal: Achieve medical castration (testosterone <50 ng/dL)

Therapeutic Objectives:

1. Primary: Testosterone suppression to castrate levels
2. Tumor Control: Slow androgen-dependent tumor growth
3. Palliative Benefit: Reduce symptoms, improve quality of life
4. Convenience: Annual implant vs. monthly/quarterly injections

Post-Vantas Landscape (2021+): Since Vantas discontinuation, histrelin is no longer the standard for prostate cancer. The archetype now filled by:

• Leuprolide depot (Lupron, Eligard)
• Goserelin (Zoladex)
• Degarelix (GnRH antagonist - avoids flare)
• Relugolix (oral GnRH antagonist)

Off-Label Supprelin LA Considerations:

• ~10x cost of former Vantas
• Not FDA-approved for prostate cancer
• May be used in exceptional circumstances
• Insurance coverage unlikely

Gender-Affirming Care Archetype

Patient Profile:

• Age: Typically Tanner stage 2-3 (early puberty)
• Diagnosis: Gender dysphoria with informed consent
• Goal: Reversible puberty suppression pending further gender exploration

Therapeutic Objectives:

1. Primary: Halt development of unwanted secondary sex characteristics
2. Time Extension: Allow psychological maturation before irreversible decisions
3. Reversibility: Preserve option for natal puberty resumption
4. Bridge Therapy: Transition to gender-affirming hormones when appropriate

Histrelin Advantages in This Population:

• Extended duration reduces healthcare encounters
• Consistent suppression without breakthrough
• Well-studied in pediatric populations
• Fully reversible upon discontinuation

Duration Considerations:

• May extend beyond 12 months (research supports 24+ months)
• Treatment continues until decision for hormones or puberty resumption
• Extended use studies show efficacy to 65 months in some cases

16. Age-Stratified Dosing

Pediatric Dosing (Central Precocious Puberty)

Standard Protocol:

• Single dose: One 50 mg histrelin implant
• Duration: Replace every 12 months (or extended per clinical judgment)
• No weight-based adjustment: Fixed implant, uniform release rate

Age-Specific Considerations:

Treatment Initiation by Age:

Very Young (2-4 years):

• Often most severe/progressive CPP
• Longest expected treatment duration
• Higher anesthesia requirements
• Consider extended implant use (2-year cycles) to minimize procedures

Middle Childhood (5-7 years):

• Moderate CPP severity typical
• 4-6 year expected treatment course
• Transitional anesthesia needs

Older Children (8-10 years):

• Often milder CPP presentation
• Shorter treatment duration expected
• Better procedure tolerance

Discontinuation Age Guidelines:

• Girls: Remove implant around age 11 (unless individual factors warrant earlier/later)
• Boys: Remove implant around age 12 (unless individual factors warrant earlier/later)
• Decision based on: chronological age, bone age, growth potential, psychosocial readiness

Adolescent Dosing (Gender-Affirming Care)

Protocol:

• Same 50 mg implant as CPP
• Initiation typically at Tanner 2-3
• Extended duration acceptable (12-24+ months per implant)
• Continue until transition to gender-affirming hormones or decision to resume natal puberty

Age-Specific Approach:

Adult Dosing (Historical - Prostate Cancer)

Vantas Protocol (Discontinued):

• One 50 mg implant annually
• Release rate: 50 mcg/day (vs. 65 mcg/day for Supprelin LA)
• Standard for all adult prostate cancer patients
• No renal/hepatic dose adjustment

Current Adult Options: Histrelin implant no longer recommended for adults due to:

1. Vantas discontinuation
2. Supprelin LA cost (~$45,000 vs. ~$5,400)
3. Supprelin LA not FDA-approved for prostate cancer
4. Multiple alternatives available (leuprolide, goserelin, degarelix, relugolix)

Special Population Dosing

Obese Pediatric Patients:

• Same implant used regardless of BMI
• Insertion technique adjusted (ensure subcutaneous, not too deep)
• Efficacy maintained across weight ranges
• Monitor for adequate suppression

Renal/Hepatic Impairment:

• No dose adjustment established
• Standard implant used
• Peptidase metabolism (non-hepatic) suggests hepatic impairment safe
• Renal impairment: metabolites cleared renally; monitor but no adjustment

17. Drug Interactions

Clinically Significant Interactions

QT-Prolonging Medications (Moderate-High Risk):

GnRH agonist-induced androgen deprivation can contribute to QT prolongation, particularly relevant in adult/prostate cancer use but applicable to all patients.

Bone-Active Medications:

Glycemic Control Medications (Prostate Cancer Context):

Androgen deprivation increases insulin resistance:

• Sulfonylureas: Monitor for hypoglycemia initially, then hyperglycemia
• Insulin: May require dose adjustment
• Metformin: Generally safe; may need dose increase

Moderate Interactions

Anticoagulants:

• Warfarin: INR monitoring around surgical procedures
• DOACs: Hold per surgical protocols for insertion/removal
• Antiplatelet agents: Consider holding for procedure

Thyroid Medications:

• No direct interaction
• Monitor thyroid function if symptoms arise
• TSH not affected by histrelin

Calcium/Vitamin D:

• No interaction
• Supplementation often recommended during GnRH agonist therapy
• Support bone health during treatment

No Significant Interactions

Safe Combinations (Common Pediatric Medications):

• Antibiotics (except QT-prolonging)
• Antihistamines (most)
• NSAIDs (short-term)
• Acetaminophen
• Asthma medications (inhaled corticosteroids, bronchodilators)
• ADHD medications (stimulants, non-stimulants)
• Standard childhood vaccines

Why Few CYP450 Interactions: Histrelin is metabolized by peptidases, not hepatic cytochrome P450 enzymes. This eliminates the majority of drug-drug interactions seen with small molecule drugs metabolized through CYP3A4, CYP2D6, etc.

Procedural Drug Considerations

Pre-Insertion/Removal:

Anesthesia Interactions:

• No contraindications to local anesthetics
• No specific general anesthesia concerns
• Standard pediatric sedation protocols apply

Supplement Interactions

No Significant Interactions:

• Multivitamins
• Omega-3 fatty acids
• Probiotics
• Most herbal supplements

Theoretical Concerns (Limited Evidence):

• Phytoestrogens (soy, flaxseed): Could theoretically counteract suppression; clinical significance uncertain
• DHEA: Would counteract treatment goals; should be avoided
• Black cohosh: Weak estrogenic activity; avoid during treatment

18. Bloodwork Impact

Expected Laboratory Changes

Hormonal Markers (Therapeutic Effect):

Timeline of Hormonal Changes:

• Week 1-2: Initial surge (LH, FSH, sex steroids increase)
• Week 2-4: Transition to suppression
• Week 4+: Full suppression achieved
• Steady state: Maintained throughout implant duration

Bone Markers:

Metabolic Panel:

• Generally unchanged in pediatric CPP patients
• Adult prostate cancer patients (Vantas): Monitor glucose, HbA1c
• No significant impact on electrolytes, renal function, liver enzymes

Monitoring Schedule

Initial Assessment (Pre-Treatment):

Month 1 Post-Insertion:

Months 3-6:

Annual (Pre-Replacement):

Laboratory Interpretation

Successful Suppression Criteria:

• LH: <0.3 IU/L (basal) or flat GnRH stimulation response
• FSH: Suppressed (less reliable marker)
• Estradiol (girls): <10-15 pg/mL
• Testosterone (boys): <20 ng/dL
• Clinical: No progression of Tanner staging

Breakthrough (Suppression Failure) Indicators:

• Rising LH despite implant in place
• Estradiol/testosterone returning to pubertal range
• Resumption of pubertal progression clinically
• Positive GnRH stimulation response

Actions for Breakthrough:

1. Confirm implant still present and palpable
2. Repeat hormonal testing to confirm
3. Consider earlier implant replacement
4. Evaluate for implant dysfunction or extended use beyond efficacy window

Incidental Findings

Expected Abnormalities (Not Concerning):

• Suppressed sex hormones (therapeutic)
• Suppressed gonadotropins (therapeutic)
• Slowed bone age advancement (therapeutic)

Unexpected Findings Requiring Evaluation:

• Elevated prolactin (evaluate for pituitary pathology)
• Thyroid abnormalities (unrelated; evaluate separately)
• Elevated liver enzymes (not expected; investigate)
• Anemia (not expected; investigate)

19. Protocol Integration

Integration with Growth Monitoring Protocols

Height Optimization Protocol:

The primary non-hormonal goal of CPP treatment is maximizing adult height. Integration approach:

Bone Age Integration:

• Bone age X-ray at baseline, then every 6-12 months
• Target: Bone age advancement slower than chronological age
• Optimal outcome: Bone age "catches up" to chronological age during treatment
• Discontinuation timing: Consider when bone age appropriate for pubertal onset

Integration with Endocrinology Follow-Up

Visit Schedule Integration:

Coordinator Role:

• Schedule surgical procedures
• Insurance prior authorization
• Specialty pharmacy coordination
• Growth chart maintenance

Integration with Surgical/Procedural Protocols

Pre-Procedure Checklist:

• Insurance authorization confirmed
• Implant ordered and received
• Anesthesia type determined (local vs. sedation vs. general)
• NPO instructions provided (if sedation/general)
• Anticoagulant management plan (if applicable)
• Consent obtained
• Previous implant removal planned (if replacement)

Day of Procedure:

• Implant at room temperature
• Sterile field prepared
• Emergency equipment available
• Anesthesia team ready (if needed)
• Post-procedure monitoring plan

Post-Procedure Protocol:

• Wound care instructions provided
• Activity restrictions (48-72 hours arm rest)
• Pain management (acetaminophen/ibuprofen typically sufficient)
• Follow-up appointment scheduled
• Warning signs reviewed (infection, allergic reaction)

Integration with Behavioral Health Monitoring

Behavioral Side Effect Protocol:

GnRH agonists can cause behavioral changes in pediatric patients. Integration:

Referral Triggers:

• Behavioral changes impacting school/home function
• Suicidal ideation or self-harm
• Pre-existing psychiatric condition worsening
• Family concern despite reassurance

Integration with Gender-Affirming Care Protocols

Multidisciplinary Team Integration:

Protocol Milestones:

1. Initial evaluation: Mental health assessment, Tanner staging
2. Treatment initiation: After informed consent, at Tanner 2-3
3. Maintenance: Regular monitoring, ongoing mental health support
4. Decision point: Continue suppression vs. initiate hormones vs. resume natal puberty
5. Transition: Coordinate hormone initiation or implant removal

Integration with Insurance/Prior Authorization

Documentation Requirements:

• Diagnosis code (ICD-10): E30.1 (precocious puberty)
• GnRH stimulation test results
• Bone age report
• Pediatric endocrinologist attestation
• Previous treatment history (if step therapy required)

Appeal Strategy (if denied):

1. Letter of medical necessity from specialist
2. Peer-to-peer review request
3. Cite AAP/Endocrine Society guidelines
4. Document needle phobia or injection failure (if applicable)
5. Calculate total cost with injection alternatives (may favor implant)

Integration with Extended Use Protocols

Beyond 12-Month Use (Research-Supported):

Evidence supports extended implant duration (up to 24+ months) in selected patients:

Extended Use Monitoring (Beyond 12 Months):

• More frequent hormonal monitoring (every 3-4 months)
• Clinical assessment for breakthrough signs
• Document continued implant integrity
• Plan for removal/replacement when suppression wanes

20. References

1. Endo Pharmaceuticals. Supprelin LA (histrelin acetate) subcutaneous implant Prescribing Information. Malvern, PA; 2022.

2. FDA Drug Approval Package: Supprelin LA (histrelin). NDA 022058. 2007.

3. FDA Drug Approval Package: Vantas (histrelin implant). NDA 021732. 2004.

4. Endo Pharmaceuticals. Vantas Discontinuation Notice. September 2021.

5. Neely EK, Silverman LA, Geffner ME, et al. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Clin Endocrinol Metab. 2014;99(4):E724-E730.

6. Silverman LA, Neely EK, Geffner ME, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab. 2015;100(6):2354-2363.

7. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704.

8. Payne KA, Myers K, Geffner ME, Walvoord EC. Extended use of histrelin implant in pediatric patients. Transgend Health. 2023;8(3):272-276.

9. Lee PA, Klein K, Mauras N, et al. Histrelin implants for suppression of puberty in youth with gender dysphoria: a comparison of 50 mcg/day (Vantas) and 65 mcg/day (Supprelin LA). Transgend Health. 2021;6(1):64-67.

10. Badouraki M, Karatza AA, Tsipouras N. Severe allergic reaction following histrelin implant (Supprelin LA). Ann Pediatr Endocrinol Metab. 2015;20(4):220-223.

11. Children's Hospital of Philadelphia. Supprelin LA (Histrelin) Subcutaneous Implant Procedure. Patient Education Materials. 2024.

12. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-e762.

13. Klein KO, Phillips SA. Review of hormone replacement therapy in girls and adolescents with hypogonadism. J Pediatr Adolesc Gynecol. 2019;32(5):460-468.

14. MedlinePlus. Histrelin Implant. U.S. National Library of Medicine. 2024.

15. DrugBank Online. Histrelin. Accessed December 2024.

Paper completed: December 2024 Research paper for educational and clinical reference purposes

Status: PAPER 62 OF 76 COMPLETE

Next Paper: #63 - Buserelin